Cytek Biosciences, Inc. CTKB Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s other accrued liabilities?
- Cytek Biosciences, Inc. (CTKB) reported other accrued liabilities of $22.17M in Q1 2026.
- How has Cytek Biosciences, Inc.'s other accrued liabilities changed year-over-year?
- Cytek Biosciences, Inc.'s other accrued liabilities increased by 72.7% year-over-year, from $12.84M to $22.17M.
- What is the long-term trend for Cytek Biosciences, Inc.'s other accrued liabilities?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s other accrued liabilities has grown at a 29.7% compound annual growth rate (CAGR), from $4.63M to $16.98M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.